Open AccessClinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
Author(s) -
Lin Weiqin,
Chattranukulchai Pairoj,
Lee Alex PW,
Lin YenHung,
Yu WenChung,
Liew HoungBang,
Oomman Abraham
Publication year - 2022
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.23882
Subject(s) - medicine , intensive care medicine , transthyretin , clinical practice , cardiomyopathy , presentation (obstetrics) , health care , perspective (graphical) , diagnostic test , medline , pathology , heart failure , pediatrics , family medicine , surgery , cardiology , artificial intelligence , computer science , economics , economic growth , political science , law
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a debilitating and life‐threatening condition with a heterogeneous clinical presentation. Recent guidelines from the United States and Europe have been published to guide clinical practice and to facilitate management conformity by covering current diagnostic and treatment strategies for patients with ATTR‐CM. These guidelines highlight the importance of an early diagnosis to optimize therapeutic outcomes, specifying the use of tests and imaging techniques to allow accurate, noninvasive diagnosis of ATTR‐CM. However, as regional practice variations across Asia may limit access to healthcare, availability of specific tests, and expertise in assessing diagnostic images, there is an ongoing need to provide an Asian perspective on these clinical guidelines. This review article provides practical recommendations for the diagnosis and monitoring of patients with ATTR‐CM in Asia, highlighting the need for additional guidelines to support a broad and diverse population, consider differing healthcare systems and diagnostic testing availability, and provide a flexible yet robust algorithm.